Malaysia-based private equity firm Xeraya Capital announced on Wednesday its participation in a globally syndicated $50 million Series C investment in Congenica, a UK-headquartered digital health company that claims to provide rapid and accurate analysis of complex genomic data.
The round was co-led by the UK-based Legal & General and Tencent Holdings. While Xeraya Capital came in as a new investor, the round also saw the participation of the company’s existing investors, namely Cambridge Innovation Capital, Downing, and Parkwalk, it said in a statement. Other new investors included Oman’s IDO Investments and China’s Puhua Capital.
“We are very pleased to be participating alongside a powerful syndicate of global investors…accelerating rapid diagnosis and initiating personalised treatment using the Congenica platform will ease suffering and save countless lives,” said Xeraya CEO Fares Zahir.
The new funding will help the company increase its footprint in the international market and expand into somatic cancer treatments, wellness and through partnerships with pharmaceutical companies, per a statement.
Xeraya has been rather active in the investment circle this year.
In June, the PE firm invested an undisclosed amount in US-based GreenLight Biosciences. The funding was routed through MLS Capital Fund II, co-managed by the US-based Spruce Capital Partners.
Prior to that, in May, Xeraya backed the US-headquartered Rapid Micro Biosystems Inc, a provider of rapid microbial detection technology for biopharma manufacturing. Besides, Xeraya also invested in GreenLight Biosciences, when it raised an additional sum of $17 million from new and existing investors including Baird Capital and global investment firm Flu Lab. The investment was made through Greenlight Pandemic Response Inc, a special purpose vehicle of GreenLight Biosciences, Xeraya Capital CEO Fares Zahir told DealStreetAsia in May.